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Introduction: Post-traumatic arthritis (PTA) is a progressive, degenerative response to joint injury, such as articular
fracture. The pro-inflammatory cytokines, interleukin 1(IL-1) and tumor necrosis factor alpha (TNF-α), are acutely
elevated following joint injury and remain elevated for prolonged periods post-injury. To investigate the role of local
and systemic inflammation in the development of post-traumatic arthritis, we targeted both the initial acute local
inflammatory response and a prolonged 4 week systemic inflammatory response by inhibiting IL-1 or TNF-α
following articular fracture in the mouse knee.
Methods: Anti-cytokine agents, IL-1 receptor antagonist (IL-1Ra) or soluble TNF receptor II (sTNFRII), were administered
either locally via an acute intra-articular injection or systemically for a prolonged 4 week period following articular fracture
of the knee in C57BL/6 mice. The severity of arthritis was then assessed at 8 weeks post-injury in joint tissues via histology
and micro computed tomography, and systemic and local biomarkers were assessed in serum and synovial fluid.
Results: Intra-articular inhibition of IL-1 significantly reduced cartilage degeneration, synovial inflammation, and did not
alter bone morphology following articular fracture. However, systemic inhibition of IL-1, and local or systemic inhibition of
TNF provided no benefit or conversely led to increased arthritic changes in the joint tissues.
Conclusion: These results show that intra-articular IL-1, rather than TNF-α, plays a critical role in the acute inflammatory
phase of joint injury and can be inhibited locally to reduce post-traumatic arthritis following a closed articular fracture.
Targeted local inhibition of IL-1 following joint injury may represent a novel treatment option for PTA.Introduction
Osteoarthritis (OA) is a debilitating disease character-
ized by degenerative changes in articular cartilage, bone,
and other surrounding tissues. Of the nearly 27 million
Americans with symptomatic OA, an estimated 12% have
a post-traumatic etiology, making post-traumatic arthritis
(PTA) one of the leading causes of joint disability [1,2].
The financial burden of PTA is significant, as it is esti-
mated to cost the US economy over $7 billion annually in
work productivity and medical expenses [1]. Additionally,* Correspondence: olson016@mc.duke.edu
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reason for US service members not returning to active
duty [3]. PTA can develop after a variety of joint injuries
including soft tissue injuries such as ligament and menis-
cal tears [4-6], articular impact [7,8] or articular fracture
[9]. Articular fractures are of particular interest, as they
commonly and predictably cause accelerated joint degen-
eration [10]. The current standard of care for articular
fractures is surgical reduction and fixation. Yet, surgical
intervention alone does not prevent the development of
PTA. Even with optimal treatment, displaced articular
fractures of the lower extremity have exhibited a 10 to
20% incidence of clinically significant arthritic degener-
ation of joint tissues [11].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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not fully understood, and a variety of factors including
chondrocyte death, altered joint mechanics, and inflamma-
tion have been implicated in the disease. Following joint
injury, elevated synovial fluid levels of pro-inflammatory
cytokines, interleukin-1 (IL-1) and tumor necrosis factor-
alpha (TNF-α), have been reported with the highest levels
observed acutely within the first 24 h after injury [12-15].
However, levels remain elevated for weeks to months post-
trauma [14,16-19]. Upregulation of IL-1 and TNF-α may
play a significant role in the pathogenesis of PTA, similar
to their role in chronic OA of joint tissue in patients with-
out antecedent injury [20,21]. Clinically, cartilage-derived
biomarkers are significantly increased within the first
month following knee injury [13,22,23], which suggests
that significant cartilage damage is occurring within weeks
of trauma and that early intervention may influence the
long-term sequela of joint degeneration [24].
In order to further characterize arthritis development
following joint trauma, we developed a murine model of
closed articular fracture of the tibial plateau with progres-
sive arthritic changes in the bone, articular cartilage, and
other joint tissues [25] at 8 weeks post-injury in C57BL/6
mice. However, the MRL/MpJ strain of mice known as the
superhealer strain was protected from PTA and did not de-
velop degenerative joint changes following articular frac-
ture [19], and exhibited lower levels of both local and
systemic inflammation in MRL/MpJ mice compared to
C57BL/6 mice [26]. This attenuated inflammatory response
may help explain how MRL/MpJ mice are protected from
the development of PTA after articular fracture [19]. These
findings also suggest that the controlled inhibition of
the inflammatory response, either systemically or lo-
cally, may represent a novel therapeutic approach for
PTA after joint injury.
Targeted blocking of specific pro-inflammatory cyto-
kines has been the focus of several therapies for rheumatic
diseases such as rheumatoid arthritis. This approach has
led to the development of specific inhibitors of IL-1, such
as anakinra (Kineret®, Biovitrum, Stockholm, Sweden), a
recombinant form of human IL-1 receptor antagonist (IL-
1Ra). Endogenous and recombinant IL-1Ra act similarly
in competitively inhibiting the binding of both IL-1α and
IL-1β to their active receptor [27]. Specific inhibitors
of TNF-α have also been developed, such as etanercept
(Enbrel®, Amgen, Thousand Oaks, CA), a human soluble
form of TNF-α receptor II (sTNFRII). sTNFRII binds dir-
ectly to TNF to block its interaction with cell-surface TNF
receptors and modulate the biological responses induced
or regulated by TNF. Previous research has shown that
administration of either IL-1Ra [28] or TNF inhibitors
[29-31] reduces inflammation and cartilage destruction in
mouse models of collagen-induced arthritis. IL-1Ra was
also shown to enhance meniscal repair in an in vitromodel [32]. However, it is unclear how these inflammatory
mediators if administered following joint injury would in-
fluence synovial inflammation and cartilage degeneration
following intra-articular trauma. Although a role for IL-1
and TNF-α in the pathogenesis of arthritis has been sug-
gested, the role of pro-inflammatory cytokines in the pro-
gression of PTA has not been elucidated. Using these
cytokine inhibitors after joint injury may represent a novel
therapeutic approach for PTA.
We have previously demonstrated that an acute and pro-
longed increase in the inflammatory response following
joint injury has been associated with the development of
arthritis in mice. To investigate the role of inflammation in
the progression of arthritis following articular fracture, we
targeted pro-inflammatory cytokines first, during the initial
acute local response to joint injury, and secondly, syste-
mically for a prolonged 4 week period following injury.
Following closed intra-articular fracture in the C57BL/6
mouse knee, the anti-inflammatory agents IL-1Ra (ana-
kinra) or sTNFRII (etanercept) were administered, either
locally via a single intra-articular injection immediately fol-
lowing injury or systemically for 4 weeks following injury,
and the severity of arthritis was assessed.
Methods
Closed articular fracture model in the mouse knee
All procedures were approved by the Duke University In-
stitutional Animal Care and Use Committee. Male C57BL/
6 mice (n = 62, Charles River, Wilmington, MA) were ob-
tained at 8 weeks of age and housed until 16 weeks of age,
at which time active growth has decreased, and peak bone
mass is achieved [33,34]. All animals received a moderate
closed articular fracture of the tibial plateau as previously
described [25]. Animals were anesthetized and placed on a
custom cradle. With the left hind limb in a neutral position
of 90° of flexion, a 10-N compressive preload was applied to
the tibial plateau using a materials testing system (Electro-
Force ELF3200; Bose, Framingham, MA, USA) via a custom
indenter. The tibia was then loaded in compression at a rate
of 20 N/second to induce fracture. The displacement of the
indenter was limited to 2.7 mm during loading, which re-
sults in moderately severe fractures. No fixation or surgical
intervention was employed. Animals were given analgesic
(buprenorphine, 48 h) following fracture induction and
allowed immediate ad libitum weight-bearing and motion.
All animals were sacrificed 8 weeks post injury.
Acute local and prolonged systemic drug delivery
Either saline, IL-1Ra (anakinra, Kineret®, Biovitrum,
Stockholm, Sweden) or sTNFRII (etanercept, Enbrel®,
Amgen, Thousand Oaks, CA, USA) were delivered follow-
ing fracture (n = 6 to 9 per group). For the local inhibition
group, animals received a single intra-articular injection im-
mediately following fracture of saline (6 μl, n = 7), IL-1Ra
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temic inhibition group, saline, IL-1Ra, or sTNFRII was ad-
ministered for 4 weeks following fracture. Due to the
short half-life and method of action of IL-1Ra, either daily
subcutaneous injections or continuous infusion was re-
quired. For this study, systemic IL-1Ra was delivered by
continuous infusion at a dosage of 1.0 mg/day [35,36]
using subcutaneously implanted osmotic pumps (model
2004; Alzet; Durect, Cupertino, CA, USA) [37]. Pumps
loaded with either IL-1Ra (n = 9) or saline (n = 9) were im-
planted immediately following fracture for a duration of
4 weeks. For systemic administration of sTNFRII, the
method of delivery was intraperitoneal (IP) injections at a
dose of 0.2 mg/day [38,39]. Either sTNFRII (n = 9) or sa-
line (n = 9) was administered three times per week for a
duration of 4 weeks starting on the day of fracture.
When administered systemically at the indicated dos-
age, both clinically available drugs have been shown to
be effective at reducing inflammatory arthritis in mur-
ine models [28,40-45].
Serum drug levels
Serum levels of delivered IL-1Ra and sTNFRII were mea-
sured by collecting blood from the maxillary vein in live
mice. To ensure the safety of the animals, blood was col-
lected at 2-week intervals from each animal. For mice re-
ceiving local intra-articular drug delivery immediately after
fracture, early time points following intra-articular injec-
tion were chosen for blood collections, day 1, 3, 14 and 15
or 18 post fracture. Due to limited sample remaining fol-
lowing quantification of delivered IL-1Ra, sufficient quan-
tities of serum from the intra-articular saline group for
quantification of sTNFRII were only available at the day-14
time point. For mice receiving systemic sTNFRII or saline
delivered via IP injections for 4 weeks following fracture,
weekly and bi-weekly time points were chosen for blood
collections, day 1, 7, 14, 28 and 42 post fracture. For mice
receiving systemic IL-1Ra or saline for 4 weeks following
fracture delivered via a subcutaneous osmotic pump, due
to technical challenges, blood was only sampled on the last
day of drug delivery at 4 weeks post fracture. Blood was
centrifuged at 10,000 g for 5 minutes, and serum was
stored at −80°C until analyzed. Due to limited volumes of
blood collected from live mice, samples were pooled by
time point to provide sufficient volume necessary for
analysis. Serum levels of delivered drugs were measured
using human IL-1Ra and sTNFRII commercially available
enzyme-linked immunosorbent assays (ELISA kit; IL-1Ra,
DRA00B; sTNFRII DRT200; R&D Systems, Minneapolis,
MN, USA). To assess the effect of drug delivery, native
levels of mouse IL-1Ra or sTNFRII were quantified in
serum obtained at time of sacrifice in those animals that
received either drug using commercially available ELISA
kits (IL-1Ra, MRA00; sTNFRII, MRT20; R&D Systems).Sample and tissue collection
All mice were sacrificed at 8 weeks post fracture. Serum
was collected via retro-orbital bleed followed by a car-
diac stick. Synovial fluid was collected from both knees
using a calcium sodium alginate compound [46]. Serum
and synovial fluid were stored at −80°C until analyzed.
After sacrifice and limb harvest, both hind limbs were
placed in 10% neutral-buffered formalin for 72 h.
Bone morphology
The knee joints of both fractured and contralateral control
limbs were scanned by a micro computed tomography
(microCT) system (microCT 40, Scanco Medical AG,
Bassersdorf, Switzerland) to assess bone morphology. A hy-
droxyapatite calibration phantom was used to scale values
(mg/cm3). Morphometric parameters of fully calcified bone
were determined using a direct three-dimensional approach
[47,48] in the distal femoral condyles, proximal tibial plat-
eau immediately distal to subchondral bone, and metaphy-
seal region of tibia beginning at fibular attachment [25].
Parameters reported in the femoral condyles were cancel-
lous bone fraction (bone volume/total volume) for the tra-
becular bone only and bone mineral density (mg/cm3).
Parameters reported in the tibial plateau were bone volume
(mm3), bone fraction, and bone mineral density, and in the
tibial metaphysis bone volume and bone mineral density.
Histological assessment of articular cartilage and
synovium
All limbs were decalcified (Cal-Ex Decalcification Solu-
tion, Fisher Scientific, Pittsburgh, PA) for 72 h, processed,
and paraffin-embedded for histology using a commercially
available automated tissue processor (ASP300S, Leica
Microsystems, Leica Biosystems, Buffalo Grove, IL). Histo-
logical sections were taken at 8 μm in the coronal plane of
the joint. Sections that captured the tibiofemoral articula-
tion were selected. In each quadrant the lateral tibia (LT),
lateral femur (LF), medial tibia (MT), and medial femur
(MF) was evaluated separately. The degree of arthritic
changes was assessed from Safranin-O- and fast-green-
stained sections using a modified Mankin score [25,49,50].
The maximum possible score was 30 for each quadrant.
The scores from all quadrants were summed for a total
joint score with a possible maximum joint score of 120.
For H&E-stained sections, the degree of synovial inflam-
mation was assessed using a standardized synovitis score
[15,51], which evaluates the synovial insertion of each
quadrant for synovial lining thickness and cellular density
in the synovial stroma. The maximum score for each
quadrant was 6. A medial and lateral side synovitis score
was summed from the associated quadrants with a max-
imum score of 12 per side of the joint. A total of three
graders, blinded to treatment group, scored all specimens.
The mean scores of the three graders were used for
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grader reliability of the synovitis score was evaluated using
Krippendorff ’s alpha.
Serum and synovial fluid biomarkers
Due to the limited volumes of blood and synovial fluid col-
lected, it was not feasible to perform analyses in duplicate,
therefore for each of the analytes, a single value was ob-
tained. Osteocalcin, a measure of osteoblast activity and
bone formation, was measured in mouse serum, diluted
5-fold as directed, using a sandwich ELISA (Biomedical
Technologies, Inc, #BT-470, Stoughton, MA, USA). A
competitive ELISA was used to quantify C-terminal telo-
peptides of type I collagen (CTX-I) in mouse serum (IDS,
RatLaps EIA, Scottsdale, AZ, USA), which is a measure of
osteoclast activity and bone resorption. For detection of
type II collagen degradation products of C-terminal telo-
peptides of type II collagen (CTX-II), a sandwich ELISA
(IDS, Serum Pre-clinical Cartilaps) was used. Serum sam-
ples were run undiluted as directed. Two different sand-
wich ELISAs were employed for the determination of free
active (FA) transforming growth factor (TGF)-β1 (BioLe-
gend, #437707, San Diego, CA, USA) and total TGF-β1
(BioLegend, #436707). Samples were run undiluted for FA
TGF-β1 and diluted 1,000-fold for total TGF-β1 as recom-
mended by the manufacturer. Serum and synovial fluid
IL-6 levels were measured using a commercially avail-
able ELISA kit specific for mouse IL-6 (R&D Systems,
M6000B). Serum samples were run undiluted as recom-
mended and synovial fluid samples were diluted 5-fold.
Values obtained for synovial fluid samples were multi-
plied by 5 to account for the assay dilution as well as by
50 to account for the dilution factor introduced by the
collection method employed. A competitive ELISA (MD
Bioproducts, #M046012, St Paul, MN, USA) was used
to quantify cartilage oligomeric matrix protein (COMP)
in synovial fluid samples. Samples were diluted 5-fold
and final values were multiplied by 5 to account for this
dilution as well as by 50 to account for the dilution fac-
tor introduced by the collection method employed.
Statistical analysis
All statistical analyses were performed using Statistica 7
software (StatSoft, Tulsa). Statistical analysis of arthritis se-
verity from the Mankin score was performed using re-
peated measure two-way analysis of variance (ANOVA)
(with the Fisher least significant difference (LSD) test post
hoc) with limb as the repeated factor and treatment group
as the second factor. Statistical analysis of synovitis, serum,
and synovial fluid measures were performed by non-
parametric analyses using Wilcoxon matched pairs for
comparison of fractured and contralateral control limbs,
and Kruskal-Wallis ANOVA for comparison among treat-
ment groups. Statistical analysis of changes in bonemorphology were performed using the one-sample t-test
to test if differences between fractured and contralateral
control limbs were significantly different to 0, and one-
way ANOVA (with Fisher LSD test post hoc) to test for
significant differences among treatment groups. Spear-
man’s rank-order correlation coefficient, rs, was deter-
mined to assess the strength of the association between
outcome measures. For all tests, significance was re-
ported at the 95% confidence level.
Results
Treatment groups following closed articular knee fracture
in mice
Moderate articular fractures that were typically located in
the lateral aspect of the tibial plateau were successfully
created in 60 mice. However, not all mice completed the
study at 8 weeks post fracture for analysis due to various
complications including pump implantation and health is-
sues unrelated to treatment. Therefore, at 8 weeks post
fracture (the time of sacrifice), we had a sample population
of n = 52 consisting of the following: intra-articular local
saline (n = 7), intra-articular IL-1Ra (n = 8), intra-articular
sTNFRII (n = 8), systemic saline via osmotic pump (n = 7),
systemic IL-1Ra via osmotic pump (n = 6), systemic saline
via IP injections three times weekly (n = 9) and systemic
sTNFRII via IP injections three times weekly (n = 7). For
all outcome measures, the two methods of systemic ad-
ministration of saline were compared. Because no signifi-
cant differences were detected for any of the outcome
measures in mice receiving systemic saline via osmotic
pump or IP injections, all mice receiving systemic admin-
istration of saline were combined for statistical analyses.
Longitudinal serum quantification confirms drug delivery
during treatment
For mice receiving local intra-articular drug delivery, serum
levels were quantified at early time points (Table 1). Levels
of both delivered IL-1Ra and sTNFRII peaked on day 1 and
remained detectable at day 3. However, both were undetect-
able in the circulation by day 14. Serum quantification of
locally delivered drugs demonstrated that local intra-
articular injection of either IL-1Ra or sTNFRII into the joint
space subsequently migrated to the serum on days 1 and 3
and was cleared fully from the circulation by day 14.
Serum levels of the drugs delivered either locally via a
single intra-articular injection immediately following frac-
ture or systemically for 4 weeks following fracture. Deliv-
ered drugs were measured in serum using human IL-1Ra
and human sTNFRII commercially available ELISAs. Data
are presented as mean ± standard deviation.
For mice receiving either systemic saline or IL-1Ra via
an osmotic pump, serum levels of delivered IL-1Ra were
measured at 4 weeks post fracture, 1 day prior to pump
removal (Table 1). Serum levels of delivered IL-1Ra levels
Table 1 Serum drug levels during treatment
Time, days Local saline Local drug








Serum levels of systemically delivered IL-1Ra, pg/ml 28 3 36,000






NA- sample was Not Available for testing.
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the upper limit of the ELISA range, and the systemic
saline group exhibited no detectable levels. For mice re-
ceiving either systemic sTNFRII or saline via IP injections
three times weekly for 4 weeks post fracture, serum levels
of delivered sTNFRII in the systemic sTNFRII group were
maximal on day 1 and remained at similar levels on day 7
with lower levels on days 14 and 28 (Table 1). Minimal
levels were detected on day 42 and undetectable levels on
day 56. The systemic saline group exhibited no detectable
levels of sTNFRII. The serum levels confirmed that the
systemic sTNFRII group received a substantial systemic
dose of the drug. The reduction in day-14 and day-28
serum levels of sTNFRII, despite continued treatment
throughout this time course with sTNFRII, was most likely
due to the formation of antibodies to the administered
sTNFRII. Similar systemic administration of sTNFRII in
mice has been effective in reducing inflammatory arthritis,
but some mice have developed antibodies to hsTNFRII
after 1 week of administration, and all mice developed
antibodies after 4 weeks of administration [52]. Levels of
mouse IL1-Ra or sTNFRII were quantified in serum at the
time of sacrifice to determine if the mice expressed native
IL-1Ra or sTNFRII in response to treatment. There was
no significant effect of either local or systemic delivery of
human IL-1Ra or sTNFRII on native levels at 8 weeks post
injury [Additional file 1].
Reduction in joint degeneration with local IL-1Ra following
articular fracture
For local intra-articular (IA) delivery following articular
fracture, the saline group demonstrated significantdegenerative changes in the fractured limb, including
loss of cartilage structure and proteoglycan staining on all
articular surfaces of the knee joint (Figure 1A). The frac-
tured limb in the local saline group had significantly
higher total joint Mankin scores compared to the contra-
lateral control limb (P = 0.02) (Figure 1B). For local IL-
1Ra, the articular fractures were evident on histologic
sections, but there were minimal degenerative changes in
the joint with no statistically significant differences in
Mankin scores between the fractured and contralateral
control limbs (P = 0.37). For local sTNFRII, fibrocartilage
was frequently found at the fracture site, and some loss of
cartilage structure and proteoglycans was observed, but
there was no significant increase in Mankin score in the
fractured limb compared to the contralateral limb (P =
0.18). Local intra-articular IL-Ra resulted in significantly
lower Mankin scores in the fractured limb compared to
saline (P = 0.03) but sTNFRII did not (P = 0.38).
Systemic delivery of saline following articular fracture
demonstrated similar results to the local intra-articular sa-
line in terms of cartilage degenerative changes. The frac-
tured limb showed loss of cartilage structure and staining
with significantly greater Mankin scores compared to the
contralateral control limb (P = 0.03). Systemic IL-1Ra deliv-
ery following articular fracture was associated with signifi-
cant degenerative changes with frequent complete loss of
articular cartilage and the presence of fibrocartilage. In con-
trast to local treatment with IL-1Ra, systemic treatment
with IL-1Ra resulted in significantly higher Mankin scores
in the fractured limbs compared to contralateral control
limbs (P = 0.001). Systemic treatment with sTNFRII was as-
sociated with the frequent appearance of fibrocartilage at
Figure 1 The effect of local intra-articular and systemic administration of IL-1 receptor antagonist (IL-1Ra) and soluble TNF receptor II
(sTNFRII) on degenerative changes in joint tissues following articular fracture. Histologic images of knee joints stained with Safranin-O
(red) and fast green (green) following fracture (F = femur, T = tibia, M =meniscus, white arrow = articular fracture, yellow arrow = fibrocartilage),
and total joint Mankin score of arthritic degenerative changes in joint tissues for contralateral control and fractured limbs following local
intra-articular (IA) administration of saline, IL-1Ra and sTNFRII (A-B) and systemic administration of saline, IL-1Ra and sTNFRII (C-D).
Data presented as mean + standard deviation (*significant difference between limbs, #significant differences between treatment groups).
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glycan staining, with altogether significantly greater Mankin
scores compared to contralateral control limbs (P = 0.04).
Systemic IL-Ra resulted in significantly higher Mankin
scores in the fractured limb compared to the fractured
limbs in both saline (P = 0.0001) and sTNFRII (P = 0.007).
Reduction in synovitis with local IL-1Ra following articular
fracture
The reliability of the synovitis scores was high for both
inter-grader reliability, α = 0.908, and intra-grader reliabil-
ity, α = 0.958. The articular fractures were typically located
in the lateral aspect of the tibial plateau. All fracture
groups, independent of treatment, had significantly higher
synovitis scores on the lateral side of the fractured limb
compared to the contralateral control limb (Figure 2A).
This increased synovitis on the lateral side is consistent
with proximity to the location of the articular fractures.
Local intra-articular IL-Ra resulted in significantly lower
lateral synovitis scores in the fractured limb compared to
the local sTNFRII fracture limb (P = 0.04). However, on
the medial side of the joint, the local saline group also
demonstrated significantly increased synovitis in thefracture limb compared to the contralateral control limb,
indicating global synovial inflammation throughout the
joint following fracture. The local IL-1Ra group demon-
strated no statistically significant differences in synovitis
scores on the medial side of the joint between fractured
and contralateral control limbs (Figure 2A). The local IL-
1Ra group demonstrated a thin cell-lining layer and low
cellular density (Figure 2B). The local sTNFRII group also
showed no statistically significant differences in synovitis
scores on the medial side of the joint between fractured
and contralateral control limbs and demonstrated less
synovitis on the medial side of the joint compared to the
lateral side of the joint.
Systemic saline demonstrated significant synovitis on
both the lateral and medial side of the joint in the frac-
tured limb compared to the contralateral control limb
(Figure 2C). However, both systemic IL-1Ra and sTNFRII
were different from the local administration in that the
fractured limb demonstrated significantly increased syno-
vitis compared to the contralateral control limb on both
the lateral and medial side of the joint, which indicated
that the global synovial inflammation throughout the joint
following fracture was not attenuated with systemic
Figure 2 The effect of local intra-articular and systemic administration of IL-1 receptor antagonist (IL-1Ra) and soluble TNF receptor II
(sTNFRII) on synovial inflammation of the knee joint following articular fracture. Synovitis scores of lateral and medial sides of knee joints
for contralateral control and fractured limbs and histologic images of synovium stained with H&E on the medial side of joint with femur (F), tibia
(T), and synovial lining near medial meniscus (M) identified by black arrows following local intra-articular (IA) administration of saline, IL-1Ra and
sTNFRII (A-B) and systemic administration of saline, IL-1Ra and sTNFRII (C-D). Data presented as mean + standard deviation (*significant difference
between limbs, #significant difference between treatment groups).
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temic IL-1Ra was trending towards increased synovitis on
the medial side of the fractured joint compared to sys-
temic sTNFRII (P = 0.08).
Bone morphological changes following fracture with local
or systemic administration of saline, IL-1Ra, or sTNFRII
Articular fracture has been reported to induce decreases in
bone volume fraction and bone mineral density in the peri-
articular tibial plateau [15,19,25]. We assessed the effect of
local or systemic administration of saline, IL-1Ra or sTNRII
on bone morphology following fracture. Within the tibial
plateau, the changes in bone fraction in the fractured limbs
normalized to the contralateral control limbs following frac-
ture were not statistically different from zero for local saline,
IL-1Ra, or sTNFRII groups (Figure 3A). However, local
sTNFRII administration following fracture resulted in sig-
nificantly reduced tibial plateau bone fraction compared to
both local saline and IL-1Ra. Systemic saline demonstrated
reduced bone fraction following fracture but the normalized
difference between fractured and control limbs was not sig-
nificantly different than zero. Both systemic IL-1Ra and sys-
temic sTNFRII had reduced tibial plateau bone fractionfollowing fracture that were significantly different than zero,
but were not statistically different to systemic saline.
Tibial plateau bone density was reduced following frac-
ture with local and systemic administration of saline, IL-
1Ra, or sTNFRII (Figure 3B). No significant reduction in
bone density was observed following articular fracture for
the local saline group. However, local IL-1Ra and local
sTNFRII resulted in a significant reduction of bone density.
Changes in bone density were greater with local sTNFRII
compared to local saline and trended toward being greater
than local IL-1Ra (P = 0.07). Groups administered systemic
saline, IL-1Ra or sTNFRII had significantly reduced tibial
plateau bone density but were not significantly different
from each other.
Within the tibial plateau, local saline and IL-1Ra adminis-
tered following fracture demonstrated similar bone morph-
ology, whereas local sTNFRII resulted in reduced bone
fraction (Figure 3C). Bone morphology changes after frac-
ture were greater with systemic administration of saline, IL-
1Ra, or sTNFRII as demonstrated by reduced bone fraction
with IL-1Ra and sTNFRII (Figure 4D). Similar bone mor-
phological changes were found in the femoral condyles and
the tibial metaphysis [Additional file 2].
Figure 3 The effect of local intra-articular and systemic administration of IL-1 receptor antagonist (IL-1Ra) and soluble TNF receptor II
(sTNFRII) on bone morphology of the tibial plateau following articular fracture. (A) Bone fraction and (B) bone density of the fractured
limb as normalized to the contralateral control limb of each mouse for the tibial. Data presented as mean ± standard deviation (*difference
between paired limbs is significantly different to zero, #significant difference between means in treatment groups). Representative axial micro
computed tomography (microCT) images of the tibial plateau following (C) local intra-articular and (D) systemic administration of IL-1Ra and
sTNFRII at 8 weeks following articular fracture. Bar, 1 mm.
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correlation between histological assessments of arthritic
changes, synovial inflammation, and bone morphology
following articular fracture
To better characterize PTA disease progression following
articular fracture, the relationship between synovial in-
flammation and arthritic changes in the joint were exam-
ined by correlating Mankin and synovitis scores for all
groups (Table 2). Interestingly, for the fractured joints,
medial Mankin and synovitis scores were significantly cor-
related (rs = 0.61). However, significant correlation was notFigure 4 Synovial fluid levels of Cartilage oligomeric matrix protein (
fracture for contralateral control and fractured limbs with (A) Local intra-art
antagonist (IL-1Ra) and soluble TNF receptor II (sTNFRII) (*significant differefound in the lateral joint scores for the fractured limbs,
nor in the contralateral control joints.
Bone morphological changes following articular fracture
also correlated with both severity of arthritic changes and
the degree of synovial inflammation (Table 2). Increasing
total joint Mankin scores in the fractured limbs correlated
with degenerative changes in bone morphology, including
decreasing bone volume (rs = −0.39) and bone density
(rs = −0.29) in the tibial plateau and decreasing cancel-
lous bone fraction (rs = −0.48) in the femoral condyles.
Similarly, synovitis in both the lateral and medial sidesCOMP) were elevated with fracture. Synovial fluid levels following
icular (IA) and (B) systemic administration of saline, IL-1 receptor
nce between limbs).
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Significant Spearman correlations, rs, between Mankin scores of arthritic changes, synovitis scores, and bone morphology parameters following articular fracture in
the knee indicate a complex interaction among joint tissues with PTA disease progression (correlation coefficients in boldface text are statistically significant,
P <0.05).
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generative changes in bone morphology. Although the
articular fractures were located on the lateral aspect of
the tibial plateau, the medial side demonstrated the
greater correlation with periarticular bone in the tibia
and femur of the knee joint, including cancellous bone
fraction in the femoral condyles (rs = −0.48), bone vol-
ume (rs = −0.25) and bone tissue density (rs = −0.48) of
the tibial plateau. The association of joint inflammation
with arthritic changes and degenerative bone changes
on the medial side of the joint, away from the lateral tib-
ial plateau fractures, suggests that global interactions
throughout the whole joint may play a role in the pro-
gression of arthritis following articular fracture.
Serum and synovial fluid biomarkers
Biomarkers of bone metabolism showed minimal dif-
ferences with treatment following fracture. Local intra-
articular sTNFRII showed a trend in increased serum
osteocalcin (P = 0.08) and an increase in serum CTX-I fol-
lowing fracture (Table 3). No differences in either bone
marker were found with systemic treatment groups fol-
lowing fracture. Serum levels of FA TGF-β1 were not sig-
nificantly different with local delivery of saline, IL-1Ra, or
sTNFRII following fracture. Total TGF-β1 was signifi-
cantly lower with local sTNFRII compared to local saline
or local IL-1Ra. However, the ratio of FA/total TGF-β1
was not significantly different between local treatment
groups. For systemic groups, there was a trend in increas-
ing FA TGF-β1 with systemic IL-1Ra delivery (P = 0.07),no difference in total TGF-β1, and a significantly higher
ratio of FA/total TGF-β1 with systemic IL-1Ra com-
pared to systemic sTNFRII. Interestingly, TGF-β1 levels
inversely correlated in both limbs with tibial plateau
bone volume (FA TGF-β1: control limb, rs = −0.33; frac-
tured limb, rs = −0.47) and bone fraction (total TGF-β1:
control limb, rs = −0.54; fractured limb, rs = −0.51), and
the FA/total TGF-β1 ratio inversely correlate inversely
with tibial plateau bone volume in both limbs (control
limb, rs = −0.36; fractured limb, rs = −0.47).
Serum IL-6 levels following fracture were significantly
greater with local sTNFRII than local IL-1Ra but not local
saline (Table 3). With systemic IL-1Ra and systemic
sTNFRII, there was a trend in elevated serum IL-6 levels
compared to systemic saline (P = 0.09). In contrast to the
serum levels, synovial fluid levels of IL-6 were lower in
both limbs with local sTNFRII compared to local IL-1Ra
but not different to local saline. With systemic administra-
tion, the trends in synovial fluid IL-6 levels were similar to
serum levels. Synovial fluid IL-6 in the control limbs
trended toward being increased with systemic IL-1Ra and
sTNFRII compared to systemic saline and was greater in
the fractured limb with systemic IL-1Ra compared to both
systemic saline and sTNFRII. Synovial fluid levels of IL-6
were not statistically different between control and frac-
tured limbs in all groups.
Synovial fluid levels of COMP were significantly greater
in fractured limbs compared to contralateral control limbs
in all groups with fracture (Figure 4). However, there were
no statistically significant differences in COMP levels with
Table 3 Biomarkers and cytokines
Local - saline Local - IL-1Ra Local - sTNFRII P (Kruskal-Wallis) Systemic - saline Systemic - IL1-Ra Systemic - sTNFRII P (Kruskal-Wallis)
Serum osteocalcin, ng/ml 7.3 ± 9.0 11.1 ± 6.7 111.4 ± 199.5§ 0.08 11.1 ± 11.3 10.6 ± 9.9 10.6 ± 9.9 0.93
Serum CTX-I, ng/ml 17.3 ± 7.4a 15.9 ± 3.6a 34.2 ± 24.6b 0.03 22.5 ± 16.6 23.0 ± 14.1 19.9 ± 9.9 0.73
Serum free active (FA) TGF-β1, pg/ml 19.1 ± 8.2 20.7 ± 10.3 22.4 ± 11.4 0.97 22.8 ± 11.9 34.3 ± 8.0§ 20.2 ± 19.1 0.07
Serum total TGF-β1, pg/ml 121,025 ± 45,854a 108,251 ± 17,183a 84,573 ± 12,760b 0.004 95,781 ± 24,239 99,868 ± 4,063 90,003 ± 11,717 0.18
Serum FA/total TGF-β1 (x 10−3) 0.18 ± 0.09 0.19 ± 0.08 0.27 ± 0.14 0.50 0.23 ± 0.10a,b 0.34 ± 0.07a 0.24 ± 0.25b 0.048
Serum CTX-II 5.7 ± 10.1 5.7 ± 7.7 3.8 ± 5.3 0.83 2.4 ± 3.1 1.7 ± 4.4 2.7 ± 4.6 0.88
Serum IL-6, pg/ml 32.5 ± 41.5a,b 6.3 ± 2.8a 67.0 ± 103b 0.004 17.6 ± 35.6 57.9 ± 78.0§ 48.3 ± 77.2§ 0.09
SF IL-6 control limb, pg/ml 1,294 ± 319a,b 1,348 ± 531a 626 ± 505b 0.02 523 ± 657 1,333 ± 365§ 1,197 ± 1,675§ 0.08
SF IL-6 fractured limb, pg/ml 1,513 ± 977a,b 1,238 ± 299a 820 ± 500b 0.04 730 ± 595a 1,370 ± 587b 653 ± 486a 0.04
Serum and synovial fluid (SF) measures of the bone turnover markers osteocalcin and C-terminal telopeptides of type I collagen (CTX-I), cartilage derived CTX-II, joint-tissue-related growth factor TGF-β1, and the cytokine IL-6.
Data are presented as mean ± standard deviation. Data with different letters are statistically different from each other (P <0.05) as measured by Kruskal-Wallis with multiple comparison of the mean ranks. P-values of the
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sTNFRII following articular fracture for fractured or
contralateral control limbs. Synovial fluid COMP levels
correlated with increasing synovitis scores in the lateral
side of the fractured limbs (rs = 0.29) and inversely corre-
lated with cancellous bone fraction in the femoral condyles
of the fracture limbs (rs = −0.25). Interestingly, COMP syn-
ovial fluid levels increased with Mankin scores, but the
correlation was not statistically significant (rs = 0.177,
P = 0.18). Serum levels of CTX-II were not significantly
different between those receiving local or systemic delivery
of saline, IL-1Ra, or sTNFRII following fracture.
Discussion
Increasing evidence from clinical and animal studies in-
dicates that pro-inflammatory cytokines are elevated
following joint injury, yet the specific roles of IL-1 and
TNF-α in the development of post-traumatic arthritis are
not fully understood. Here, we show that early local inhib-
ition of IL-1 with a single intra-articular injection of IL-1Ra
significantly reduced arthritic changes in cartilage, reduced
synovitis, and did not alter bone morphology or bone heal-
ing after a closed joint fracture in mice. Local inhibition of
TNF-α with a single intra-articular injection of sTNFRII
had a moderate effect in reducing arthritic changes in the
cartilage and synovitis, although not as effectively as IL-
1Ra. However, degenerative changes in bone morphology
were not reduced with sTNFRII. Systemic infusion of IL-
1Ra for 4 weeks post injury, and both local and systemic
inhibition of TNF-α with either a single intra-articular in-
jection of sTNFRII or three times weekly injections of
sTNFRII for 4 weeks did not reduce arthritic changes, and
instead led to significant degenerative changes in bone
morphology and evidence of fibrous fracture healing. These
results show that intra-articular IL-1, rather than TNF-α,
plays a critical role in the acute inflammatory phase follow-
ing joint injury and can be inhibited locally to reduce post-
traumatic arthritis following a closed articular fracture.
While the role of anti-cytokine therapy in PTA remains
to be firmly established, its role in autoimmune mouse
models of arthritis is relatively well-characterized. For ex-
ample, continuous high doses of systemic IL-1Ra prevents
collagen-induced arthritis (CIA) in DBA/1 mice [35]. Fur-
thermore, chronic overexpression of TNF using a human
TNF-transgenic mouse model of TNF-induced arthritis
has been shown to be best reduced with a treatment of
anti-TNF-antibody (infliximab) and recombinant human
IL-1Ra (anakinra) [42]. When administered concurrently,
combination therapy of infliximab and anakinra has been
shown to block proteoglycan loss in a synergistic fashion
[42]. However, systemic cytokine inhibition in the present
study did not demonstrate any benefit in reducing PTA,
suggesting that future efforts should target intra-articular
methods of therapeutic administration. Given that IL-1Ra(anakinra) is commercially available and Food and Drug
Administration (FDA)-approved for the treatment of
rheumatoid arthritis, the results of the current investiga-
tion have broad therapeutic implication and support the
extension of translational studies and potential clinical tri-
als in humans. To date, there has been one pilot study of
anakinra for acute joint injury in humans [53]; this trial
showed that IL-1Ra, administered intra-articularly within
the first month following severe knee injury, reduced knee
pain and improved function over a 2-week interval. How-
ever, the ability of IL-1 inhibition to reduce the develop-
ment of PTA was not addressed.
In contrast, for treatment of chronic OA, previous clin-
ical trials have reported that neither systemic nor local in-
hibition of IL-1 were able to reduce clinical symptoms in
patients with symptomatic OA of the knee. Systemic in-
hibition of IL-1 with human monoclonal antibody to IL-1
receptor 1 administered for 12 weeks was found to be
well-tolerated, and showed a trend in pain reduction, but
the effect was not significant, and the clinical benefit was
small [54]. Local inhibition of IL-1Ra with a single intra-
articular injection of human recombinant IL-1Ra (ana-
kinra) was also shown to be well-tolerated but only showed
a reduction of pain at 4 days and no improvement in OA
symptoms compared to placebo at 4, 8, and 12 weeks [55].
Pharmacokinetic data indicate that the mean terminal
half-life of IL-1Ra in serum after intra-articular injection is
approximately 4 h and is undetectable at 24 h. With the
acute local inhibition of IL-1 in this study, we observed less
cartilage degeneration and less synovial inflammation. We
were also able to detect IL-1Ra in serum up to three days
after intra-articular injection, potentially because of de-
creased clearance due to joint swelling following injury.
Our results support a direct role for IL-1 in the acute in-
flammatory phase of articular injury that can be inhibited
at the injury site by exogenous administration of IL-1Ra to
reduce PTA.
The systemic IL-1Ra group had the most severe arthritic
changes demonstrated by the highest Mankin and syno-
vitis scores. It is important to consider the role of IL-1 in
the healing response to fracture. IL-1β was found to sti-
mulate proliferation and differentiation of pre-osteoblasts
in vitro, as MC3T3-E1 cells produced more mineralized
bone matrix when IL-1β was introduced [56]. Moreover,
IL-1β can alter the ratio of cartilage volume to callus vol-
ume in mice following a diaphyseal tibial fracture within
two weeks after the injury [56]. The dosage and timing of
administration of the 4-week continuous systemic infusion
of IL-1Ra was selected based on previous data showing its
effectiveness in ameliorating arthritis in mouse models of
inflammatory arthritis [35-37]. However, in our articular
fracture model, this strategy of systemic IL-1Ra deliv-
ery appears to have altered the healing response. Given
our findings, along with previous evidence suggesting a
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lated that IL-1 may transition from playing a negative role
in the acute phase of trauma to a positive role in the heal-
ing and bone remodeling phase.
In this study, acute local inhibition of TNF-α or systemic
inhibition of TNF-α for 4 weeks post injury did not pre-
vent the progression of PTA. From histological evaluations,
fibrous healing could be observed at the site of fracture
8 weeks post-injury with administration of sTNFRII. Like-
wise, bone morphology assessed with microCT indicated
that bone fraction and bone density were significantly re-
duced with administration of sTNFRII. Our findings sug-
gest that inhibiting TNF-α following articular fracture may
inhibit fracture healing and bone remodeling. This is
consistent with results in a model of simple closed fracture
repair in wild-type and TNF-α receptor-deficient mice
wherein the absence of TNF-α signaling led to impaired
fracture healing [57]. We also found that detrimental
changes in bone morphology were correlated to histologic
measures of cartilage degeneration and synovial inflam-
mation. This demonstrates the complex inter-relationship
between the various joint tissues in the development of
post-traumatic arthritis.
We have previously reported reduced bone fraction and
bone mineral density following fracture [15,19]. However,
these degenerative bone changes appear to be reduced in
the local saline group along with the local IL-1Ra group.
The data suggest that intra-articular injections of saline
may be altering the intra-articular environment in a man-
ner which is beneficial to the periarticular bone. One hy-
pothesis is that intra-articular injections may be diluting
catabolic factors or washing out the joint. However, local
saline provided no benefit in reducing cartilage degener-
ation or synovial inflammation. Normal fracture healing
involves the upregulation of many inflammatory cytokines
and growth factors, and the temporal profiles of these fac-
tors are different during the healing process [58,59]. The
cytokines IL-1β and TNF-α have also been shown to
stimulate the production of active bone morphogenetic
protein 2 (BMP-2) [60], which may be involved in the re-
pair process. Understanding the role of such systemic fac-
tors found in the circulating serum following trauma may
provide insight into articular fracture healing and the de-
velopment of PTA. Although we saw differences in bone
morphology between treatment groups, systemic measures
of bone turnover were not significantly different among
treatment groups following fracture. We found that
markers of both osteoblast and osteoclast activity in-
creased with increasing bone volume or bone fraction in
the tibial plateau and metaphysis at 8 weeks post fracture.
This time point would represent the remodeling phase of
bone repair and has been characterized by high levels of
bone resorption and formation markers [61]. Bone turn-
over markers vary throughout the fracture healing process,and although biochemical markers of bone-turnover have
been helpful in understanding and clinical treatment of
metabolic bone disease like osteoporosis, their usefulness
in assessing fracture healing has not been established [62].
TGF-β1 may play a role in endochondral ossification [63],
and is reported to be activated during osteoclast bone re-
sorption [64,65]. In this study, increasing total or free ac-
tive TGF-β1 was associated with decreased bone volume
and bone fraction in the tibial plateau. TGF-β1 promotes
bone formation through chemotactic attraction of osteo-
blasts and the enhancement of osteoblast proliferation
[66]. However, bone-resorbing osteoclasts may help to re-
lease free active TGF-β1 via their acidic microenvironment
[67,68]. Longitudinal assessment of systemic markers of
bone turnover and healing may provide more insight into
our understanding of articular fracture healing and lead to
new methods of assessing interventions that may prevent
or mitigate the development of PTA.
Serum IL-6 concentrations were significantly lower in
mice that received local IL-1Ra following articular fracture
compared to those that received local sTNFRII, and no dif-
ferences in synovial fluid concentrations of IL-6 were
found between fractured and contralateral limbs among
any groups. IL-6 is reported to be elevated in synovial fluid
following meniscal and ligamentous tears [12,69]. However,
IL-6 serum concentrations significantly decrease during
fracture healing [70], which may explain the minimal dif-
ferences among treatment groups at 8 weeks post fracture.
Interestingly, serum and synovial fluid IL-6 concentrations
increased with increasing cartilage degenerative changes in
the medial tibia following articular fracture. In vitro studies
have demonstrated that IL-6 influences cartilage cata-
bolism with mechanical trauma resulting in increased pro-
teoglycan loss [71]. IL-6 with the soluble IL-6 receptor
triggered osteoclast formation and has also been associated
with osteoclast-like cell formation in rheumatoid arthritis
patients and may contribute to bone resorption [72,73],
which supports our observation of an association between
increased synovial fluid IL-6 concentrations and decreasing
bone fraction in the medial tibial plateau. Serum IL-6 also
correlated with increased synovitis scores following articu-
lar fracture. The interaction between inflammatory cyto-
kines like IL-1, TNF-α and IL-6 following joint trauma is
not well-understood. However, in this mouse model of
joint injury, the data suggest a complex relationship be-
tween systemic and local biochemical factors and joint
pathology of the cartilage, synovium and adjacent bone.
The progression of PTA following joint injury is not
well-characterized, and current clinical measures are un-
able to predict which patients may develop PTA following
injury. Identifying serum or synovial fluid molecular bio-
markers of degenerative joint changes following injury
would provide insight into the early stages of the disease
and be a useful and relatively noninvasive diagnostic tool.
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between fractured and contralateral control limbs at 8 weeks
post fracture. COMP is an extracellular matrix protein
found predominantly in cartilage, but also in synovium,
meniscus, ligaments, tendons, and associated with osteo-
blasts [74-76]. COMP has been suggested as a candidate
biochemical molecular marker of arthritis because of its
relative specificity to joint tissues. Interestingly, synovial
fluid COMP correlated with synovitis and decreased bone
fraction but not cartilage degenerative changes. Although
COMP has been used as a marker of cartilage turnover
[76], COMP has also been reported to be associated with
clinical synovitis in patients with knee OA [77], elevated
in injured tendon sheath synovial fluid [78], and expressed
by adult osteoblasts and may be indicative of metabolic
bone activity [74]. In this study, synovial fluid COMP was
not significantly different among treatment groups. How-
ever, COMP was only measured at a single time point of
8 weeks post fracture. Longitudinal analysis of COMP
may provide more insight in future studies.Conclusion
This study indicates that acute treatment of an articular
fracture with local IL-1Ra therapy can prevent cartilage
degeneration and synovial inflammation in the mouse
knee. Our investigation supports a direct role for IL-1 in
the acute phase of the inflammatory process that follows
articular injury. These results further our understanding of
the biological mechanisms governing PTA and provide
evidence to support the therapeutic benefit of a novel
method of treating acute joint injuries that may be used as
adjunctive therapy to surgical stabilization.Additional files
Additional file 1: Native serum levels of mouse IL-1Ra or soluble
TNF receptor II (sTNFRII). Native levels of mouse IL-1Ra or sTNFRII were
quantified in serum obtained at time of sacrifice in those animals that
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following articular fracture.
Additional file 2: Bone morphology measured by micro computed
tomography (microCT). Bone morphology was assessed for the
contralateral control (R) and fractured limbs (L) in the tibial plateau, tibial
metaphysis, and femoral condyles.Abbreviations
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